Cost-effectiveness of childhood rotavirus vaccination in Germany

Aidelsburger, Pamela; Grabein, Kristin; Böhm, Katharina; Dietl, Markus; Wasem, Jürgen; Koch, Judith; Ultsch, B.; Weidemann, Felix; Wichmann, Ole

doi:10.1016/j.vaccine.2014.01.061

Cited by 25 publications

(10 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incremental cost-effectiveness ratio was calculated as incremental costs divided by incremental quality-adjusted lift year (QALY) gained, in order to determine the priority to purchasing the interventions at different budget levels. The health utility of different disease status were derived from previous literature [30]. A willingness-to-pay (WTP) thresholds of three times Gross Domestic Product (GDP) per capita was applied to examine the cost-effectiveness of the vaccination options, as WHO defined interventions with ICER less than three times of GDP per capita as cost-effective and that less than GDP per capita as very cost-effective [31].…”

Section: Methodsmentioning

confidence: 99%

Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option

Cui

Tobe

et al. 2016

BMC Infect Dis

View full text Add to dashboard Cite

BackgroundRotavirus infection causes considerable disease burden of acute gastroenteritis (AGE) hospitalization and death among children less than 5 years in China. Although two rotavirus vaccines (Rotarix and RotaTeq) have been licensed in more than 100 countries in the world, the Lanzhou Lamb rotavirus vaccine (LLR) is the only vaccine licensed in China. This study aims to forecast the potential impacts of the two international vaccines compared to domestic LLR.MethodsAn economic evaluation was performed using a Markov simulation model. We compared costs at the societal aspect and health impacts with and without a vaccination program by LLR, Rotarix or RotaTeq. Parameters including demographic, epidemiological data, costs and efficacy of vaccines were obtained from literature review. The model incorporated the impact of vaccination on reduction of incidence of rotavirus infection and severity of AGE indicated by hospitalization, inpatient visits and deaths. Outcomes are presented in terms of quality-adjusted life years (QALYs) gained and incremental cost-effectiveness ratio (ICER) compared to status quo.ResultsIn a hypothetical cohort of 100,000 infants, the two international vaccines showed very good cost-effectiveness, with ICER of Rotateq and Rotarix shifting from LLR of $1715.11/QALY and $2105.66/QALY, respectively. Rotateq and Rotarix had significantly decreased incidence compared to LLR, particularly among infants aged 6 months to 2 years.ConclusionsRotaTeq is expected to introduce in the national routine immunization program to reduce disease burden of rotavirus infection with universal coverage.

show abstract

Section: Methodsmentioning

confidence: 99%

Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option

Cui

Tobe

et al. 2016

BMC Infect Dis

View full text Add to dashboard Cite

show abstract

“…2013 36 CEA (1) Immunisation(2) No immunisation DE SHI Birth cohort 100% 5 y Cases averted and savings Direct and indirect (2011, €) One-way & PSAModel sensitive to the frequency of seeking medical advice, RV disease and hospital visits Net saving: >£9 million RV Imaz et al. 2013 37 CUA (1) Immunisation(2) No immunisation ES Societal Healthcare Birth cohort 100% 5 y QALY Direct and indirect (2011, €) One-wayModel sensitive to the vaccine price, vaccine efficacy and utility values Cost/QALY:£244, 077 (healthcare)£182,982 (societal) RV Aidelsburger et al. 2014 38 CEA (1) Immunisation(s) (2) No immunisation DE SHI < 5 y 80% 5 y QALY Direct and indirect costs (2010, £) One- and 2-wayModel sensitive to herd immunity, utility values, the vaccine price and administration costs Cost/QALY: £118,187–144,208 MD Trotter et al.…”

Section: Resultsmentioning

confidence: 99%

Economic evaluation of pediatric influenza immunization program compared with other pediatric immunization programs: A systematic review

Gibson¹,

Begum²,

Sigmundsson³

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

This study compared the economic value of pediatric immunisation programmes for influenza to those for rotavirus (RV), meningococcal disease (MD), pneumococcal disease (PD), human papillomavirus (HPV), hepatitis B (Hep B), and varicella reported in recent (2000 onwards) cost-effectiveness (CE) studies identified in a systematic review of PubMed, health technology, and vaccination databases. The systematic review yielded 51 economic evaluation studies of pediatric immunisation — 10 (20%) for influenza and 41 (80%) for the other selected diseases. The quality of the eligible articles was assessed using Drummond's checklist. Although inherent challenges and limitations exist when comparing economic evaluations of immunisation programmes, an overall comparison of the included studies demonstrated cost-effectiveness/cost saving for influenza from a European-Union-Five (EU5) and United States (US) perspective; point estimates for cost/quality-adjusted life-years (QALY) from dominance (cost-saving with more effect) to ≤45,444 were reported. The economic value of influenza programmes was comparable to the other vaccines of interest, with cost/QALY in general considerably lower than RV, Hep B, MD and PD. Independent of the perspective and type of analysis, the economic impact of a pediatric influenza immunisation program was influenced by vaccine efficacy, immunisation coverage, costs, and most significantly by herd immunity. This review suggests that pediatric influenza immunisation may offer a cost effective strategy when compared with HPV and varicella and possibly more value compared with other childhood vaccines (RV, Hep B, MD and PD).

show abstract

“…Over the last few years, several studies evaluated the cost-effectiveness of routine infant rotavirus vaccination around the world and reported varying results even studies from the same country; 20,21,[28][29][30][31][32][33][34][35] among them, 2 are from Japan. 20,21 The significant difference between our model and those of the previous studies is the incorporation of rotavirus-related encephalitis/encephalopathy, and sequelae in the model, which were not present in the previous ones.…”

Section: Discussionmentioning

confidence: 99%

Economic evaluation of routine infant rotavirus immunisation program in Japan

Hoshi

Kondo

Okubo

2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Two rotavirus vaccines are currently available in Japan. We estimated the incremental cost-effectiveness ratio (ICER) of routine infant rotavirus immunisation program without defining which vaccine to be evaluated, which reflects the current deliberation at the Health Science Council in charge of Immunisation and Vaccine established by the Ministry of Health, Labor and Welfare of Japan. Three ICERs were estimated, one from payers' perspective and 2 from societal perspective depending on the scenarios to uptake vaccines. The health statuses following the birth cohort were as follows: not infected by rotavirus, asymptomatic infection, outpatients after infection, hospitalised after infection, developing encephalitis/ encephalopathy followed by recovery, sequelae, and death.

show abstract

Cost-effectiveness of childhood rotavirus vaccination in Germany

Cited by 25 publications

References 25 publications

Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option

Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option

Economic evaluation of pediatric influenza immunization program compared with other pediatric immunization programs: A systematic review

Economic evaluation of routine infant rotavirus immunisation program in Japan

Contact Info

Product

Resources

About